Jade Biosciences

Contributing Author

Recent Articles by Jade Biosciences

Sep-30	Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026 JBIO GlobeNewswire
Sep-01	Jade Biosciences to Participate in Upcoming Conferences JBIO GlobeNewswire
Aug-10	Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update JBIO GlobeNewswire
Jun-26	Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors JBIO GlobeNewswire
Jun-05	Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares JBIO JBIO -11.57% GlobeNewswire
Jun-03	Jade Biosciences Announces Pricing of Public Offering of Common Stock JBIO GlobeNewswire
Jun-03	Jade Biosciences Announces Proposed Underwritten Public Offering JBIO GlobeNewswire
Jun-01	Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy JBIO -11.64% GlobeNewswire
May-29	Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy JBIO GlobeNewswire
May-26	Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody JBIO GlobeNewswire
May-26	Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy JBIO GlobeNewswire
May-07	Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update JBIO JBIO +6.56% GlobeNewswire
Apr-23	Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) JBIO GlobeNewswire
Apr-22	Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer JBIO +10.30% GlobeNewswire
Mar-06	Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update JBIO GlobeNewswire
Feb-11	Jade Biosciences to Participate in Upcoming Conferences JBIO GlobeNewswire
Jan-05	Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference JBIO -7.34% GlobeNewswire
Dec-15	Jade Biosciences Announces $45 Million Private Placement JBIO GlobeNewswire
Nov-13	Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update JBIO JBIO +10.54% GlobeNewswire
Nov-08	Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 JBIO GlobeNewswire
Nov-03	Jade Biosciences to Participate in Upcoming Conferences JBIO GlobeNewswire
Oct-17	Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 JBIO JBIO +6.72% GlobeNewswire
Oct-07	Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases JBIO GlobeNewswire
Oct-07	Jade Biosciences Announces $135 Million Private Placement JBIO GlobeNewswire
Sep-02	Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy JBIO GlobeNewswire
Aug-25	Jade Biosciences to Participate in Upcoming Conferences JBIO GlobeNewswire
Aug-13	Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update JBIO JBIO -7.64% GlobeNewswire
Jul-08	Jade Biosciences to Participate in Two Upcoming Investor Conferences JBIO GlobeNewswire
Jul-01	Jade Biosciences Appoints Brad Dahms as Chief Financial Officer JBIO +8.56% GlobeNewswire
Jun-09	Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy JBIO +7.23% GlobeNewswire
Jun-02	Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress JBIO GlobeNewswire
May-14	Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update JBIO -12.31% GlobeNewswire
May-13	Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference JBIO GlobeNewswire

Jade Biosciences

Recent Articles by Jade Biosciences

Upgrade your Finviz experience